Dermatitis  >>  Eucrisa (crisaborole)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Eucrisa (crisaborole) / Pfizer
CrisADe CARE 1, NCT03356977 / 2019-002836-10: A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

Completed
4
137
Canada, US, RoW
Crisaborole ointment 2%, Eucrisa
Pfizer
Atopic Dermatitis
04/19
04/19
NCT04214197: Study of Crisaborole Ointment 2% in Mild to Moderate Atopic Dermatitis

Active, not recruiting
4
150
US
Crisaborole 2% Top Oint
Massachusetts General Hospital, Pfizer
Atopic Dermatitis
07/21
08/21
NCT04023084: Response of Children With Atopic Dermatitis (Eczema) to Eucrisa

Completed
4
30
US
Crisaborole, Eucrisa
Ann & Robert H Lurie Children's Hospital of Chicago, Pfizer
Atopic Dermatitis, Eczema
02/22
02/22
NCT03832010: Steroid-reducing Effects of Crisaborole

Active, not recruiting
4
24
US
Crisaborole, Eucrisa, Hydrocortisone Ointment, Triamcinolone ointment, Aquaphor
Johns Hopkins University, Pfizer
Atopic Dermatitis, Eczema
12/24
12/24
NCT03539601 / 2018-001043-31: A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD

Terminated
3b/4
237
Europe, US
Crisaborole ointment, 2%, Eucrisa, Hydrocortisone butyrate cream, 0.1%, Locoid 0.1%, Pimecrolimus cream, 1%, Elidel, Crisaborole Vehicle
Pfizer
Atopic Dermatitis
12/20
12/20

Download Options